We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosylate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zest homolog 1 and 2, and subsequently bridged to allogeneic stem cell transplantation. Valemetostat led to a quick response and was well tolerated, offering a promising bridge therapy to transplantation for patients with relapsed/refractory peripheral T-cell lymphoma, which is still an unmet medical need.
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients / Bagnato, Gianmarco; Stefoni, Vittorio; Broccoli, Alessandro; Argnani, Lisa; Pellegrini, Cinzia; Casadei, Beatrice; Bonifazi, Francesca; Zinzani, Pier Luigi. - In: MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. - ISSN 2035-3006. - ELETTRONICO. - 16:1(2024), pp. e2024004.1-e2024004.4. [10.4084/mjhid.2024.004]
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients
Bagnato, Gianmarco;Stefoni, Vittorio;Broccoli, Alessandro;Argnani, Lisa;Pellegrini, Cinzia;Casadei, Beatrice;Bonifazi, Francesca;Zinzani, Pier Luigi
2024
Abstract
We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosylate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zest homolog 1 and 2, and subsequently bridged to allogeneic stem cell transplantation. Valemetostat led to a quick response and was well tolerated, offering a promising bridge therapy to transplantation for patients with relapsed/refractory peripheral T-cell lymphoma, which is still an unmet medical need.File | Dimensione | Formato | |
---|---|---|---|
Successful Bridging to Allogeneic Transplantation.pdf
accesso aperto
Descrizione: Successful Bridging to Allogeneic Transplantation
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
278.27 kB
Formato
Adobe PDF
|
278.27 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.